As CD30 is expressed in most T-cell lymphomas and has been safely and effectively targeted with the ADC brentuximab vedotin [55], there are efforts being made to develop a CD30-directed TCE. Here, TNFRSF8 is linked to T-cell non-Hodgkin lymphoma.